阿克他命:对其在人类中使用的范围审查。

IF 3.7 3区 医学 Q1 CLINICAL NEUROLOGY
Gustavo C Leal, Isabel Lima-Araújo, David G Roiter, Ana Teresa Caliman-Fontes, Rodrigo P Mello, Flávio Kapczinski, Acioly L T Lacerda, Lucas C Quarantini
{"title":"阿克他命:对其在人类中使用的范围审查。","authors":"Gustavo C Leal, Isabel Lima-Araújo, David G Roiter, Ana Teresa Caliman-Fontes, Rodrigo P Mello, Flávio Kapczinski, Acioly L T Lacerda, Lucas C Quarantini","doi":"10.1007/s00406-024-01945-2","DOIUrl":null,"url":null,"abstract":"<p><p>Arketamine (R-ketamine), an enantiomer of ketamine, has historically been less studied than esketamine (S-ketamine) and the racemic mixture. Recent preclinical studies suggest that arketamine may offer prolonged antidepressant effects and a superior safety profile. This scoping review aims to assess and synthesise existing literature on the clinical use of arketamine in humans. This review follows the PRISMA for Scoping Reviews guidelines, with a comprehensive search conducted in PubMed, Embase, ClinicalTrials.gov, and the WHO International Clinical Trials Registry. Eligible studies included those reporting the administration of arketamine to humans. Data were extracted and synthesised descriptively. A total of 20 studies involving 410 subjects were included. Arketamine was primarily investigated for pain management and depression. While early evidence suggests arketamine may be effective in reducing pain, most studies were small and conducted in non-clinical settings. In psychiatry, trials indicate potential antidepressant effects, but results are inconsistent, and some studies remain unpublished. A consistent observation across most studies is arketamine's favourable safety profile, showing lower incidences of dissociative and psychotomimetic effects compared to esketamine and racemic ketamine. Arketamine may have a role in pain management and psychiatry, with a favourable safety profile compared to other forms of ketamine. However, the small scale of many studies limits the generalizability of findings, and results in depression trials are mixed. Larger, well-designed studies, possibly with higher doses, are needed to determine its therapeutic potential and establish its place in clinical practice.</p>","PeriodicalId":11822,"journal":{"name":"European Archives of Psychiatry and Clinical Neuroscience","volume":" ","pages":"1317-1332"},"PeriodicalIF":3.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Arketamine: a scoping review of its use in humans.\",\"authors\":\"Gustavo C Leal, Isabel Lima-Araújo, David G Roiter, Ana Teresa Caliman-Fontes, Rodrigo P Mello, Flávio Kapczinski, Acioly L T Lacerda, Lucas C Quarantini\",\"doi\":\"10.1007/s00406-024-01945-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Arketamine (R-ketamine), an enantiomer of ketamine, has historically been less studied than esketamine (S-ketamine) and the racemic mixture. Recent preclinical studies suggest that arketamine may offer prolonged antidepressant effects and a superior safety profile. This scoping review aims to assess and synthesise existing literature on the clinical use of arketamine in humans. This review follows the PRISMA for Scoping Reviews guidelines, with a comprehensive search conducted in PubMed, Embase, ClinicalTrials.gov, and the WHO International Clinical Trials Registry. Eligible studies included those reporting the administration of arketamine to humans. Data were extracted and synthesised descriptively. A total of 20 studies involving 410 subjects were included. Arketamine was primarily investigated for pain management and depression. While early evidence suggests arketamine may be effective in reducing pain, most studies were small and conducted in non-clinical settings. In psychiatry, trials indicate potential antidepressant effects, but results are inconsistent, and some studies remain unpublished. A consistent observation across most studies is arketamine's favourable safety profile, showing lower incidences of dissociative and psychotomimetic effects compared to esketamine and racemic ketamine. Arketamine may have a role in pain management and psychiatry, with a favourable safety profile compared to other forms of ketamine. However, the small scale of many studies limits the generalizability of findings, and results in depression trials are mixed. Larger, well-designed studies, possibly with higher doses, are needed to determine its therapeutic potential and establish its place in clinical practice.</p>\",\"PeriodicalId\":11822,\"journal\":{\"name\":\"European Archives of Psychiatry and Clinical Neuroscience\",\"volume\":\" \",\"pages\":\"1317-1332\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Archives of Psychiatry and Clinical Neuroscience\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00406-024-01945-2\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Archives of Psychiatry and Clinical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00406-024-01945-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/16 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

阿氯胺酮(r -氯胺酮)是氯胺酮的对映体,历史上对它的研究少于艾氯胺酮(s -氯胺酮)及其外消旋混合物。最近的临床前研究表明,阿克他命可能提供持久的抗抑郁作用和优越的安全性。本综述旨在评估和综合现有的关于阿克他命在人类临床应用的文献。本综述遵循PRISMA范围审查指南,并在PubMed、Embase、ClinicalTrials.gov和WHO国际临床试验注册中心进行了全面检索。符合条件的研究包括那些报告人类使用阿克他命的研究。对数据进行提取和描述性合成。共纳入20项研究,涉及410名受试者。阿氯胺酮主要用于治疗疼痛和抑郁。虽然早期证据表明阿克他命可能有效减轻疼痛,但大多数研究都是在非临床环境中进行的小规模研究。在精神病学方面,试验表明潜在的抗抑郁作用,但结果不一致,一些研究仍未发表。大多数研究一致的观察结果是,阿克他命具有良好的安全性,与艾氯胺酮和外消旋氯胺酮相比,它显示出较低的解离和拟精神效应发生率。阿克他命可能在疼痛管理和精神病学中发挥作用,与其他形式的氯胺酮相比,它具有良好的安全性。然而,许多研究的小规模限制了研究结果的普遍性,并且抑郁症试验的结果好坏参半。需要更大规模、设计良好的研究,可能需要更高的剂量,以确定其治疗潜力,并确立其在临床实践中的地位。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Arketamine: a scoping review of its use in humans.

Arketamine (R-ketamine), an enantiomer of ketamine, has historically been less studied than esketamine (S-ketamine) and the racemic mixture. Recent preclinical studies suggest that arketamine may offer prolonged antidepressant effects and a superior safety profile. This scoping review aims to assess and synthesise existing literature on the clinical use of arketamine in humans. This review follows the PRISMA for Scoping Reviews guidelines, with a comprehensive search conducted in PubMed, Embase, ClinicalTrials.gov, and the WHO International Clinical Trials Registry. Eligible studies included those reporting the administration of arketamine to humans. Data were extracted and synthesised descriptively. A total of 20 studies involving 410 subjects were included. Arketamine was primarily investigated for pain management and depression. While early evidence suggests arketamine may be effective in reducing pain, most studies were small and conducted in non-clinical settings. In psychiatry, trials indicate potential antidepressant effects, but results are inconsistent, and some studies remain unpublished. A consistent observation across most studies is arketamine's favourable safety profile, showing lower incidences of dissociative and psychotomimetic effects compared to esketamine and racemic ketamine. Arketamine may have a role in pain management and psychiatry, with a favourable safety profile compared to other forms of ketamine. However, the small scale of many studies limits the generalizability of findings, and results in depression trials are mixed. Larger, well-designed studies, possibly with higher doses, are needed to determine its therapeutic potential and establish its place in clinical practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
8.80
自引率
4.30%
发文量
154
审稿时长
6-12 weeks
期刊介绍: The original papers published in the European Archives of Psychiatry and Clinical Neuroscience deal with all aspects of psychiatry and related clinical neuroscience. Clinical psychiatry, psychopathology, epidemiology as well as brain imaging, neuropathological, neurophysiological, neurochemical and moleculargenetic studies of psychiatric disorders are among the topics covered. Thus both the clinician and the neuroscientist are provided with a handy source of information on important scientific developments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信